Areteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma
Amount Raised
$75 Million
Round Type
Series A
Short HillsBiotechnologyInvestors
Description
Areteia Therapeutics announced an additional $75 million in Series A financing to support the expansion of the current Phase III development program of dexpramipexole in eosinophilic asthma.
Quick answer
Areteia Therapeutics raised $75 Million in a Series A round, dated February 13, 2024. Investors: Population Health Partners, Maverick Capital, Sanofi, Saturn Partners, ARCH Venture Partners, GV, Access Biotechnology and Bain Capital Life Sciences. Areteia Therapeutics is based in Short Hills, New Jersey, United States.
- How much did Areteia Therapeutics raise?
- Areteia Therapeutics raised $75 Million in a Series A round on February 13, 2024.
- Who invested in Areteia Therapeutics?
- Population Health Partners, Maverick Capital, Sanofi, Saturn Partners, ARCH Venture Partners, GV, Access Biotechnology and Bain Capital Life Sciences are named as investors in this round.
- What does Areteia Therapeutics do?
- Areteia Therapeutics, Inc. is a biotech company focused on advancing the Phase III program for dexpramipexol, the first potential oral medication for eosinophilic asthma.
- Where is Areteia Therapeutics based and how big is it?
- Areteia Therapeutics is based in Short Hills, New Jersey, United States. Fundz records about 27 employees.
- Who are the decision-makers at Areteia Therapeutics?
- Fundz holds 1 contact at Areteia Therapeutics, including the Director. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Biotechnology around the same time
Companies in the same sectors as Areteia Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- CESSATION THERAPEUTICS raised $1M (Seed) on March 29, 2024.
- Vaccinex raised $1.8M (Seed) on March 29, 2024.
- Terragia Biofuel raised $6M (Seed) on March 29, 2024.
- Sense4Med raised $551K (Seed) on March 29, 2024.
- Inomagen Therapeutics raised $200K (Pre-Seed) on March 29, 2024.
- ProtoKinetix raised $35K (Seed) on March 29, 2024.
Who to call at Areteia Therapeutics, and when
A new round usually means Areteia Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Areteia Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Areteia Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Areteia Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Areteia Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAreteia Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.